Abstract Library

#2902 DNA Methylation Analysis of the PDX1 Gene Can Be Used for PNET Subtyping and Has a Possible Prognostic Value

Introduction: Estimating prognosis of pancreatic neuroendocrine tumor (PNET) patients remains challenging. Mutation status of DAXX/ATRX/MEN1, histone modification patterns and immunohistochemistry for relevant transcription factors, including PDX1, were recently used to perform subtyping and distinguished two main types, A and B. These subtypes are linked to cell-of-origin and associated with clinical outcome.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Boons G, Vandamme T, Ibrahim J, Schepers A, Roeyen G,

Keywords: Pancreatic Neuroendocrine Tumor, DNA Methylation, Prognostic Biomarker,

#2877 Comparison of Digestive and Non-Digestive Neuroendocrine Neoplasm Patient Characteristics and Survival in an ENETS Center of Excellence

Introduction: Since 2016 both digestive neuroendocrine neoplasms (D-NENs) and non-digestive NENs (ND-NENs) cases are treated within NETwerk, an ENETS Center of Excellence

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Vandamme T, De Backer L, Dero I, Galdermans D, Abrams P,

Keywords: non-digestive NENs, gastroenteropancreatic NENs,

#2875 Immunotherapy as Second-line Treatment in Grade 3 Neuroendocrine Carcinomas: A Prospective Case Series from an ENETS Center of Excellence

Introduction: Metastatic WHO grade 3 extra-pulmonary neuroendocrine carcinomas (EP-NEC) have a poor prognosis and optimal treatment after first-line platinum-etoposide chemotherapy remains unclear. A recent, small phase II study combining ipilimumab and nivolumab showed promising results

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Vandamme T, De Backer L, Van den Brande J, Op de Beeck B, Driessen A,

Keywords: NEC, immunotherapy,

#2283 Ultra-Deep Targeted Resequencing Reveals Recurrent DAXX and CYFIP2 Mutations and Implicates Novel Pathways in Pancreatic Neuroendocrine Tumors

Introduction: Recent studies in pancreatic neuroendocrine tumors have identified mutations in DAXX/ATRX, MEN1, and genes involved in the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin (PI3K-Akt-mTOR) pathway. However, these studies focused on abundant mutations.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Vandamme T

Authors: Vandamme T, Beyens M, Van Camp G, Boons G, Hofland L,

Keywords: pancreatic neuroendocrine tumors, PNET, genetics, tumor heterogeneity, hotspot mutations,

#2139 Genome-Wide DNA Methylation Profiling of Pancreatic Neuroendocrine Tumors

Introduction: Frequent inactivation of epigenetic regulators ATRX and DAXX in pancreatic neuroendocrine tumors (PNETs) suggests an important role for epigenetic alterations in tumorigenesis. Few studies have been published regarding differential methylation patterns in PNETs and a thorough analysis of these alterations is currently lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Boons G, Beyens M, Schepers A, Vandamme T, Roeyen G,

Keywords: pancreatic neuroendocrine tumor, DNA methylation,